INmune Bio Inc (INMB) — Cash Flow-to-Debt Ratio
INmune Bio Inc (INMB) has a Cash Flow-to-Debt Ratio of -0.68x as of September 2025, meaning its operating cash flow of $-5.44 Million could theoretically repay -1% of its total liabilities ($7.98 Million) in one year. Check earnings quality score of INmune Bio Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
INmune Bio Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for INmune Bio Inc across 10 annual periods. Also explore balance sheet size of INmune Bio Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for INmune Bio Inc (2015–2024)
Year-by-year debt coverage analysis for INmune Bio Inc. For market capitalisation and broader financial context, see INmune Bio Inc (INMB) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.47x | $-33.36 Million | $7.46 Million | ▼ -603.6% |
| 2023 | -0.64x | $-11.98 Million | $18.86 Million | ▲ +39.3% |
| 2022 | -1.05x | $-22.69 Million | $21.69 Million | ▲ +27.6% |
| 2021 | -1.45x | $-28.50 Million | $19.72 Million | ▲ +69.3% |
| 2020 | -4.70x | $-8.94 Million | $1.90 Million | ▲ +24.9% |
| 2019 | -6.26x | $-5.38 Million | $860.54K | ▼ -150.3% |
| 2018 | -2.50x | $-2.06 Million | $823.77K | ▼ -1.6% |
| 2017 | -2.46x | $-761.83K | $309.72K | ▼ -365.6% |
| 2016 | -0.53x | $-317.38K | $600.81K | ▲ +10.3% |
| 2015 | -0.59x | $-18.12K | $30.75K | — |